ReviewDermatology and therapy2026

Lebrikizumab ADvocate1 and 2 Monotherapy and ADjoin (Long-Term) Trials: Use of Topicals Therapies.

Linda Stein-Gold et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.